Cardiol Res
Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website


Volume 10, Number 4, August 2019, pages 207-210

Lambl’s Excrescences: Current Diagnosis and Management

Ganesh Kumar K. Ammannaya

Department of Cardiovascular and Thoracic Surgery, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai 400022, India

Manuscript submitted May 28, 2019, accepted June 25, 2019
Short title: Diagnosis and Management of LE


Lambl’s excrescences (LEs) are unusual, yet significant etiology of thromboembolism. LEs are fibrous valvular strands typically occurring at coaptation lines of the left-sided valves. These occur from wear and tear of the valves and comprise of a dense core of collagenous and elastic fibrils enclosed by endothelium. Transesophageal echocardiography (TEE) remains the gold standard in its diagnosis. Asymptomatic LEs are closely monitored, while symptomatic lesions with history of thromboembolism are managed with antiplatelet drugs or are anticoagulated. Surgery is indicated in case of recurrent thromboembolic episodes occurring while on medications.

Keywords: Lambl’s excrescences; Valvular strands; Thromboembolism; Transesophageal echocardiography


Dr. Vilem Dusan Lambl first reported Lambl’s excrescences (LEs) in 1856, as filiform valvular fronds with hypermobility [1]. These cardiac processes (≤ 2 mm thick and ≥ 3 mm long), classically occur at the valve closure lines. LEs occur most commonly on the atrial side of the mitral valve (68-76%), followed by the aortic valve on the ventricular side (38-50%). LEs have also been shown to occur on prosthetic valves, and the affection of the right-sided native valves is extremely rare [2, 3]. These strands have equal incidence in men and in women.

LEs originate on the endocardial surface owing to trivial endothelial injury caused by valvular wear and tear [4-6]. Though mostly asymptomatic, LE have been shown to be associated with thromboembolic events such as cerebrovascular accidents (CVA), peripheral embolization and acute coronary syndrome. These are more common in the excrescences of the aortic valve [5].


High stress in closure lines of left-sided valves can affect a tear or a lesion in the endocardium that initiates the pathogenesis of LE. Deposition of fibrin over this injured endocardium at the surface of the valve causes endothelial overgrowth, resulting in the development of papillary outgrowths. These partially detach from the surface, hyalinize, and ultimately become fibrosed. The increasing shear forces with age further contribute to their occurrence. A cluster of LE may separate from the valve surface, leading to thromboembolism. These lesions can occur in association with rheumatic heart disease, past history of endocarditis and pulmonary or systemic hypertension, but may also occur in otherwise healthy individuals [5, 7-9].

LEs are thin (≤ 2 mm in width) and elongated (5 - 10 mm in length). Some excrescences, known as giant LEs, can be up to 2.5 cm in length. Two well-defined types of LEs can occur depending on the affected age group: lamellar excrescences which are seen more commonly in patients younger than 30 years, while filiform excrescences which occur in older patients [10].

Histologically, LEs comprise of a connective tissue center containing copious collagen and elastic fibrils, enclosed by a single layer of endothelium. The densely hyalinized central core is lined by bland-looking, endocardial-type spindle cells. The arrangement of tissues is in apposed layers, with variable collagen fibril orientation [7-11].


Most patients with LE are asymptomatic and the valvular strands are found incidentally on echocardiography [2]. However, they can be a rare cause of stroke, or coronary artery obstruction [12]. LE, particularly those found on aortic and mitral valve leaflets can break free and embolize to the brain causing stroke. The potential cause of a CVA should be identified by Doppler ultrasonography of the carotid arteries and by echocardiographic scanning of the ascending, transverse, and arch segments of the aorta [3, 4].

Transesophageal echocardiography (TEE) is recommended in causal evaluation of any stroke, because it is more sensitive than transthoracic echocardiography (TTE). However, with the development of the current high-resolution echo systems, valvular strands can often be detected on TTE [3]. On echocardiography, LE appears as independent, undulating hypermobile, strand-like structures (≤ 2 mm thick and ≥ 3 mm long) at the leaflet’s coaptation [4, 11, 13, 14].

The differential diagnosis for these excrescences includes imaging artifact, vegetations, thrombi, redundant leaflet, flap due to aortic dissection, papillary fibroelastoma, myxoma, other cardiac neoplasms and metastases. Of these, the most difficult is the distinction between LEs and fibroelastomas. Histopathologically, they are similar. However, fibroelastomas are larger, most often solitary, usually arise from the mid portion of valve leaflets and appear as pedunculated lesions on the less mechanically affected parts of valves, and on other areas of the endocardium. In contrast, LEs are multiple and arise from the line of valve closure [4, 15].


Definitive guidelines for the management of patients with LE do not exist as of today, owing to rarity of the condition and a consequent paucity of well-designed studies. The various strategies employed in the management of LE include single and dual antiplatelet therapy, anticoagulation and surgery [16], and are largely based on isolated case reports.

Asymptomatic patients with LE should be closely monitored with TEE follow-up [2]. Patients who have LE and have experienced one episode of transient ischemic attack (TIA)/CVA should be treated conservatively with antiplatelet therapy. While some authors report the use of aspirin alone [17, 18], others have advocated dual antiplatelet therapy (DAPT) with the addition of clopidogrel [14, 19]. There is no general consensus in the literature about whether to use anticoagulation [5, 20] versus antiplatelet therapy in a patient with a single embolic episode with LE.

It is recommended to include LE in the differential diagnosis of cryptogenic stroke [14] and TEE is strongly advisable in this setting [2, 14]. If LE is present, treatment with DAPT should be considered. If there is a recurrent ischemic event while on this therapy, a trial of anticoagulation therapy with warfarin or acenocoumarol should be considered, along with aspirin or DAPT before proceeding with surgical resection of the LE [14]. It is reasonable to offer surgical valve replacement after second CVA related to LE as the recurrence rate of CVA is high [15]. In a patient with poor medical compliance, surgical excision and valve replacement may be a better option for TIA/CVA symptoms secondary to LE, given the bleeding risk on antiplatelet/anticoagulation therapy [21]. A summary of the current practices in the management of LE is schematically represented in Figure 1.

Figure 1.
Click for large image
Figure 1. Current practices in the management of LE. TEE: transesophageal echocardiography; TIA: transient ischemic attack; CVA: cerebrovascular accident; DAPT: dual antiplatelet therapy.

There is a general consensus that the choice between surgical intervention versus conservative management, needs to be decided on a case-by-case basis and should be based on the pre-operative risk stratification for the patient [17].


LEs are unusual, but a proven differential diagnosis of cryptogenic stroke. TEE is still the gold standard in their diagnosis [14]. Our current understanding about the management of LE is drawn entirely from previous case reports. High-powered studies directly comparing the various modalities of treatment in different clinical settings are lacking. This emphasizes the need for statistically well-designed studies to further validate our current understanding about LE and its successful management. Till such a time, a case-specific approach with respect to decision making has to be adopted depending on the clinical status of the patient.



Financial Disclosure

None to declare.

Conflict of Interest


Author Contributions

GKKA: entire manuscript conceptualization, writing and editing.

  1. Lambl VA. Papillare exkreszenzen an der semilunar-klappe der aorta. Wien Med Wochenscshr. 1856;6:244-447.
  2. Aziz F, Baciewicz FA, Jr. Lambl's excrescences: review and recommendations. Tex Heart Inst J. 2007;34(3):366-368.
  3. Leitman M, Tyomkin V, Peleg E, Shmueli R, Krakover R, Vered Z. Clinical significance and prevalence of valvular strands during routine echo examinations. Eur Heart J Cardiovasc Imaging. 2014;15(11):1226-1230.
    doi pubmed
  4. Jaffe W, Figueredo VM. An example of Lambl's excrescences by transesophageal echocardiogram: a commonly misinterpreted lesion. Echocardiography. 2007;24(10):1086-1089.
    doi pubmed
  5. Kalavakunta JK, Peddi P, Bantu V, Tokala H, Kodenchery M. Lambl's excrescences: a rare cause of stroke. J Heart Valve Dis. 2010;19(5):669-670.
    doi pubmed
  6. Al-Ansari S, Hindori V, Riezebos RK, Yilmaz A. Multiple Lambl's excrescences with subvalvular extension, a rare cause of cryptogenic stroke: treated by port-access cardiac surgery. BMJ Case Rep. 2013;2013.
    doi pubmed
  7. Riddle JM, Wang CH, Magilligan DJ, Jr., Stein PD. Scanning electron microscopy of surgically excised human mitral valves in patients over 45 years of age. Am J Cardiol. 1989;63(7):471-477.
  8. Nighoghossian N, Derex L, Loire R, Perinetti M, Honnorat J, Riche G, Barthelet M, et al. Giant lambl excrescences. An unusual source of cerebral embolism. Arch Neurol. 1997;54(1):41-44.
    doi pubmed
  9. Aggarwal A, Leavitt BJ. Giant lambl's excrescences. N Engl J Med. 2003;349:25.
    doi pubmed
  10. Hurle JM, Garcia-Martinez V, Sanchez-Quintana D. Morphologic characteristics and structure of surface excrescences (Lambl's excrescences) in the normal aortic valve. Am J Cardiol. 1986;58(13):1223-1227.
  11. Roldan CA, Shively BK, Crawford MH. Valve excrescences: prevalence, evolution and risk for cardioembolism. J Am Coll Cardiol. 1997;30(5):1308-1314.
  12. Dangas G, Dailey-Sterling FG, Sharma SK, Chockalingham S, Albanese JR, Reich DL, Meller J, et al. Non-Q-wave infarction and ostial left coronary obstruction due to giant Lambl's excrescences of the aortic valve. Circulation. 1999;99(14):1919-1921.
    doi pubmed
  13. Freedberg RS, Goodkin GM, Perez JL, Tunick PA, Kronzon I. Valve strands are strongly associated with systemic embolization: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;26(7):1709-1712.
  14. Chu A, Aung TT, Sahalon H, Choksi V, Feiz H. Lambl's Excrescence Associated with Cryptogenic Stroke: A Case Report and Literature Review. Am J Case Rep. 2015;16:876-881.
    doi pubmed
  15. Daveron E, Jain N, Kelley GP, Luer WH, Fermin C, Helmcke F, Kerut EK. Papillary fibroelastoma and Lambl's excrescences: echocardiographic diagnosis and differential diagnosis. Echocardiography. 2005;22(3):285-287.
    doi pubmed
  16. Kariyanna PT, Jayarangaiah A, Rednam C, Hegde S, Marmur JD, Kamran H, Wengrofsky P, et al. Lambl's excrescences and stroke: a scoping study. Int J Clin Res Trials. 2018;3(2):127.
    doi pubmed
  17. Davogustto G, Fernando RR, Loghin C. Lambl's excrescence, migrainous headaches, and "tiger stripes": puzzling findings in one patient. Tex Heart Inst J. 2015;42(1):70-72.
    doi pubmed
  18. Wolf RC, Spiess J, Huber R. [Lambl's excrescence and cerebral ischemic insult]. Nervenarzt. 2006;77(12):1492-1494.
    doi pubmed
  19. Ker J. The serpentine mitral valve and cerebral embolism. Cardiovasc Ultrasound. 2011;9:7.
    doi pubmed
  20. Kamran H, Patel N, Singh G, Pasricha V, Salifu M, McFarlane SI. Lambl's excrescences: A case report and review of the literature. Clin Case Rep Rev. 2016;2(7):486-488.
    doi pubmed
  21. Osorio B, Hou L, Xu J, Pagan E, et al. Lambl's excrescences and a review of therapeutic strategies. Case Reports in Internal Medicine. 2018;5(3).

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cardiology Research is published by Elmer Press Inc.


Browse  Journals  


Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics






Cardiology Research, bimonthly, ISSN 1923-2829 (print), 1923-2837 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.

This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.